Hepatocellular carcinoma (HCC)
Conditions
Interventions
Three times injection of AFP-derived peptide within 4 weeks after diagnosis of HCC every 2 weeks
Sponsors
Department of Gastroenterology, Kanazawa University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)HCC must be diagnosed 2)Serum AFP must be positive 3)Karnofsky Performance Status is equal to or more than 70% 4)Patients must be equal to or more than 20 years old and written informed consent must be obtained 5)WBC is equal to or more than 1,500/mm3 6)Platelet is equal to or more than 30,000/mm3 7)Hb is equal to or more than 8.0 g/dl 8)Level of liver damage must be A or B 9)Serum Cr is equal to or less than 1.5 mg/dl
Exclusion criteria
Exclusion criteria: 1)Severe complications associated with heart, kidney, lung, blood and coagulability 2)Infection of HIV 3)Surgical treatment, chemotherapy and radiation therrapy within 4 weeks 4)Past medical history of immunodeficiency, splenectomy and radiation of spleen 5)medical treatments with steroid or anti-histamine 6)Patients who are during lactation 7)Patients who are during pregnancy and expected pregnancy 8)Past history of organ transplantation 9)Patients who are predicted a difficulty of following clinical course 10)Patients who are judged inappropriate for clinical trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of adverse events and immune responses | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation of anti-tumor effect and tumor marker | — |
Countries
Japan
Contacts
Public ContactEishiro Mizukoshi
Kanazawa University Hospital Gastroenterology
Outcome results
None listed